Publications : 2022

Tornero-Velez R, Dawson D, East A, Breen M, Brady S, Vallero D, Hubal EC, Wambaugh, J. Using systematic evidence mapping to track the development of toxicokinetic models of PFAS from 2000–2021. Poster presented at Society of Toxicology, San Diego, CA, March 2022, DOI: 10.23645/epacomptox.19333283, open access online.


Pharmacokinetic (PK) models characterize how dose is distributed within the body. In chemical exposure and dose research, PK models are either “classical”, generally consisting of one or two mathematically abstract compartments (i.e., central and peripheral), or explicitly physiologically-based (PBPK) with defined tissue volumes. Use of PK models for estimations of per- and polyfluoroalkyl substances (PFAS) in serum have been in use for decades. However, use of models has varied across studies by publication year, location, and referenced papers. This scoping effort seeks to systematically map the current landscape for PFAS PK models, categorizing different trends and similarities across model type, PFAS, and use scenario. A literature review using Web of Science (WOS) and the SWIFT review tool were used to identify PK models used for PFAS. The assessment covered publications from 2000-2021. The most common chemical, PFOA, was included in 69 of the 92 papers, followed by PFOS with 60. Within the corpus, 50 papers contained a one-compartment model, 17 two compartment models were found, and 33 used physiologically based pharmacokinetic (PBPK) models. The scoping assessment suggest that scientific interest has centered around two chemicals – PFOA and PFOS – and most analyses use one-compartment models in human exposure scenarios.